Novartis AG  (NVS) Trade Now »     Rate NVS  -  Discuss NVS  -  Add to Watch List        

Home

Analysis & Videos

Quotes

Bull or Bear

Discuss

NVS: Bull or Bear?

From:    SocialPicks  |  Blogsphere  |  All

SocialPicks Community

ETFI Global Healthcare Sector PerformIdex NVS

75%

-9.24% in 19 days Global Health Composite Index Representing 400 Companies The accompanying table presents the top five rated companies with market caps of at least $250 million (USD) from each of the nine new healthcare indexes developed by ETF Innovators [ETFI] from a database of about 400 companies worldwide. The ETFI Global Healthcare Sector PerformIdex consists of 45 top rated companies ranging from small-caps to mega-caps from the following underlying healthcare indexes: 1.) ETFI Global Hospitals – Fresenius Medical (FMS) 2.) ETFI New Drug Regulatory Catalyst ... Continue reading »

Teva Beats on Profits: A Biogeneric Boon in '09? NVS

75%

+1.46% in 8 days (closed on 11/14/08) Teva Beats on Profits: A Biogeneric Boon in '09? Teva Pharma (TEVA) posted 3Q08 results this morning which beat consensus profit estimates by a penny at 72 cents per share on an adjusted basis with record sales coming in slightly below estimates at $2.84B versus $2.9B expected. Revenue increased by 20% while GAAP net income of $637M rose by 21% from the year-ago period. Results were driven by the proprietary multiple sclerosis drug Copaxone, which posted sales of $562M, representing a 28% increase from the year-ago period. Cash flow from operations more than dou ... Continue reading »

My 60 Defensive Growth Stock Picks at Inner8.com NVS

75%

+3.66% in 12 days (closed on 11/06/08) My 60 Defensive Growth Stock Picks at Inner8.com The accompanying table presents my 60 defensive growth stock picks at the recently launched online investing site Inner8.com , which I wrote about yesterday. My picks are focused on healthcare and consumer staples, along with some cash rich tech companies such as Microsoft (MSFT). My picks include companies across the entire spectrum of market cap and risk in the biotech industry, ranging from top performers such as Amgen (AMGN) and Celgene (CELG) to small and micro-cap picks such as Discovery Labs (DSCO), ... Continue reading »

Expanding Defensive Growth Index into Europe NVS

75%

-4.37% in 2 days (closed on 10/25/08) Expanding Defensive Growth Index into Europe The accompanying table presents an updated version of the ETFI Highly Defensive PerformIdex, which is expanded to 40 companies with market caps of at least $10B from the industry groups listed below. This defensive growth index is heavily weighted in consumer staples and healthcare and is now structured to include companies based in Europe, in addition to the United States and Canada. Compared to the previous version, this index has a lower beta and higher average market cap and adds European companie ... Continue reading »

A Waiting Game for Momenta Pharma NVS

75%

-10.66% in 27 days (closed on 10/23/08) A Waiting Game for Momenta Pharma According to a SEC 8-K filing today, an amendment has been submitted to the FDA for Momenta Pharma's (MNTA) Enoxaparin Sodium Injection Abbreviated New Drug Application [ANDA] by its partner, Sandoz, which is the generic drug operating division of Novartis (NVS). Momenta believes the amendment represents a complete response to the agency's concerns over the potential for immune-mediated reactions to the product, which is intended to be a generic equivalent of the injectable blood thinner Lovenox. Momenta Pharma represe ... Continue reading »

From the Blogosphere

A New Global Healthcare Composite Index

75%

The accompanying table [click to enlarge or download] presents the top five rated companies with market caps of at least $250M from each of the 10 new healthcare indexes developed by ETF Innovators [ETFI] from a database of about 500 companies worldwide. The ETFI Global Healthcare Sector PerformIdex is a dynamic, semi-active index with monthly updates which consists of the 50 top-rated companies on an equal weight basis from each of the 10 healthcare indexes listed below and represents an alternative strategy to existing health composite ETFs -- which tend to have highly correlated returns ... Continue reading »

Stock Picks for Healthy Returns

75%

Abbott Labs (ABT) is a consistent performer with diversified healthcare operations, including pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents. ABT is back to the lower end of its trading range near 50 bucks, presenting an excellent entry point with a 2.8% dividend yield and forward PE of about 14X. Celgene (CELG) is also trading at the low end of its trading range around 50 bucks as a large-cap growth stock focused on cancer biotech products and research with an estimated PEG ratio below one. China Medical (CMED) is trading near its IPO levels of August 20... Continue reading »

Health Cost Containment Index: Expanding into India, Impax Labs Set to Re-List

75%

The ETF Innovators [ETFI] Global Healthcare Cost Containment Index profiled in the accompanying table is updated and expanded to include more companies from my recent Analysis of Generic Drug Companies from India. The index is structured to include companies with market caps between $150M-$60B, which are involved in producing generic healthcare products such as generic drugs and pharmacy benefit managers which do not have retail store and insurance components. The Top 10 Rated companies are sorted by market cap, with Taro Pharma (TAROF) involved in litigation with India's top generic drug co... Continue reading »

Health Cost Containment Index: Expanding into India, Impax Labs Set to Re-List

75%

The ETF Innovators [ETFI] Global Healthcare Cost Containment Index profiled in the accompanying table is updated and expanded to include more companies from my recent Analysis of Generic Drug Companies from India. The index is structured to include companies with market caps between $150M-$60B, which are involved in producing generic healthcare products such as generic drugs and pharmacy benefit managers which do not have retail store and insurance components. The Top 10 Rated companies are sorted by market cap, with Taro Pharma (TAROF) involved in litigation with India's top generic drug co... Continue reading »

Stock Picks for Healthy Returns

75%

Abbott Labs (ABT) is a consistent performer with diversified healthcare operations, including pharmaceuticals, diagnostics, medical nutrition products, and medical devices/stents. ABT is back to the lower end of its trading range near 50 bucks, presenting an excellent entry point with a 2.8% dividend yield and forward PE of about 14X. Celgene (CELG) is also trading at the low end of its trading range around 50 bucks as a large-cap growth stock focused on cancer biotech products and research with an estimated PEG ratio below one. China Medical (CMED) is trading near its IPO levels of August 20... Continue reading »

Trade NVS Now
and Get 30 Free Trades »

... more »  

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.